X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DBV712 (viaskin Peanut 250 μg) is a novel treatment designed to re-educate the immune system by introducing microgram amounts of peanut allergen to the immune system through intact skin.
Lead Product(s): Viaskin Peanut
Therapeutic Area: Immunology Product Name: DBV712
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
DBV712 (viaskin Peanut 250 μg) is a novel treatment designed to re-educate the immune system by introducing microgram amounts of peanut allergen to the immune system through intact skin.
Lead Product(s): Viaskin Peanut
Therapeutic Area: Immunology Product Name: DBV712
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
Viaskin Peanut 250 μg is a novel treatment designed to re-educate the immune system by introducing microgram amounts of peanut allergen to the immune system through intact skin.
Lead Product(s): Viaskin Peanut
Therapeutic Area: Immunology Product Name: DBV712
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
The IFU outlines that Viaskin Peanut 250 µg is to be worn for as close to a full day as possible with a minimum daily wear time of at least 12 hours each day.
Lead Product(s): Viaskin Peanut
Therapeutic Area: Immunology Product Name: Viaskin
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Viaskin Peanut demonstrated a statistically significant treatment effect (p<0.001), with 67.0% of subjects in the Viaskin Peanut arm meeting the treatment responder criteria after 12 months, as compared to 33.5% of subjects in the placebo arm.
Lead Product(s): Viaskin Peanut
Therapeutic Area: Immunology Product Name: Viaskin
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
The update is to initiate a new, pivotal Phase 3 clinical study and to demonstrate effectiveness, safety and improved in vivo adhesion of the modified Viaskin (Viaskin Peanut) patch in children in the intended patient population.
Lead Product(s): Viaskin Peanut
Therapeutic Area: Immunology Product Name: Viaskin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021
Details:
Viaskin™ is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin.
Lead Product(s): Viaskin Peanut
Therapeutic Area: Immunology Product Name: Viaskin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
New analyses of clinical studies investigating epicutaneous immunotherapy to treat peanut allergy with a patch (DBV712 250 µg) will be presented at the virtual American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
Lead Product(s): Viaskin peanut
Therapeutic Area: Immunology Product Name: DBV712
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Viaskin™ is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin.
Lead Product(s): Viaskin peanut
Therapeutic Area: Immunology Product Name: DBV712
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Food and Drug Administration has issued a Complete Response Letter regarding the Company’s Biologics License Application for investigational Viaskin™ Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.
Lead Product(s): Viaskin peanut
Therapeutic Area: Immunology Product Name: DBV712
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
